We have located links that may give you full text access.
ENGLISH ABSTRACT
JOURNAL ARTICLE
[Effects of glucagon-like peptide 1(9-36) on endothelial nitric oxide synthase in human umbilical vein endothelial cells].
Zhonghua Yi Xue za Zhi [Chinese medical journal] 2012 November 14
OBJECTIVE: To explore the effects of glucagon-like peptide 1 (GLP-1(9-36)) on endothelial nitric oxide synthase (eNOS) in human umbilical vein endothelial cells (HUVEC).
METHODS: HUVEC cultured under the conditions of normal glucose (5.5 mmol/L) or high glucose (16.8 mmol/L) were incubated with 5-5000 pmol/L GLP-1(9-36). NO production was assayed by the nitrate reductase method. The eNOS activities were detected by NOS assay kit, p-eNOS (ser-1177) level and total eNOS protein level by Western blot and eNOS mRNA level by real-time reverse transcription-polymerase chain reaction (RT-PCR).
RESULTS: Under normal glucose condition, NO productions from HUVEC of 50 - 5000 pmol/L GLP-1(9-36) groups were significantly higher than the control ((41.6 ± 8.1) µmol/L vs (22.2 ± 2.6) µmol/L, P < 0.05). So were eNOS activities in cells (1.76 ± 0.12 vs 1.00 ± 0.00, P < 0.05). Compared with the control group, the levels of eNOS phosphorylation at ser-1177, mRNA and total protein were significantly elevated in the 5000 pmol/L GLP-1(9-36) group. Under high glucose condition, GLP-1(9-36) retained all the above effects.
CONCLUSION: GLP-1 (9-36) can increase NO release, eNOS activity and expression in HUVEC. This may be one of the underlying mechanisms for the protective effects of GLP-1(9-36) on cardiovascular system.
METHODS: HUVEC cultured under the conditions of normal glucose (5.5 mmol/L) or high glucose (16.8 mmol/L) were incubated with 5-5000 pmol/L GLP-1(9-36). NO production was assayed by the nitrate reductase method. The eNOS activities were detected by NOS assay kit, p-eNOS (ser-1177) level and total eNOS protein level by Western blot and eNOS mRNA level by real-time reverse transcription-polymerase chain reaction (RT-PCR).
RESULTS: Under normal glucose condition, NO productions from HUVEC of 50 - 5000 pmol/L GLP-1(9-36) groups were significantly higher than the control ((41.6 ± 8.1) µmol/L vs (22.2 ± 2.6) µmol/L, P < 0.05). So were eNOS activities in cells (1.76 ± 0.12 vs 1.00 ± 0.00, P < 0.05). Compared with the control group, the levels of eNOS phosphorylation at ser-1177, mRNA and total protein were significantly elevated in the 5000 pmol/L GLP-1(9-36) group. Under high glucose condition, GLP-1(9-36) retained all the above effects.
CONCLUSION: GLP-1 (9-36) can increase NO release, eNOS activity and expression in HUVEC. This may be one of the underlying mechanisms for the protective effects of GLP-1(9-36) on cardiovascular system.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app